YYYue Yu

Yue Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yue Yu has a total of 204 co-authors. Here are the top co-authors by number of shared publications:

  • Xu-Chen Cao

    The First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin China

    23 shared publications
  • Xin Wang

    The First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin China

    17 shared publications
  • Xin Wang

    The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    8 shared publications
  • Di Zhang

    The First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin 300060 China

    7 shared publications
  • Zhao-Hui Chen

    The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    7 shared publications
  • Bo-Wen Liu

    The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    5 shared publications

Latest Publications

  • Open Access

    Weight‐Adjusted Waist Index and Breast Cancer Prevalence in U.S. Adult Women: A Cross‐Sectional NHANES Analysis (1999–2016)

    by Yili Li, Zhengjun Yang, Yunbo An, Yue Yu, Xuchen Cao, Xin Wang

    Background: Central adiposity, captured by the weight‐adjusted‐waist index (WWI), may correlate with breast cancer risk, but whether the association persists after adjustment for demographic and cardiometabolic confounders remains unclear. We examined the cross‐sectional association between WWI and breast cancer prevalence in U.S. adult women. Methods: Using National Health and Nutrition Examination Survey (NHANES) 1999–2016 data ( n = 6782; 208 breast‐cancer cases), we fit survey‐weighted logistic models with three levels of covariate adjustment, restricted cubic splines (RCS), and Extreme Gradient Boosting (XGBoost)‐based variable importance. Propensity‐score matching (PSM) and sensitivity analyses were performed. Results: After adjustment for age, race, poverty‐to‐income ratio (PIR), hypertension, diabetes, and coronary heart disease (CHD), the highest vs. lowest WWI quartile showed an odds ratio (OR) of 1.84 (95% CI 1.19–2.91; p = 0.008). In Shapley Additive exPlanations (SHAP) analysis of the full analytic cohort ( n = 6782), age dominated variable importance (mean |SHAP| 0.0071), followed by race (0.0016) and WWI (0.0015); this ordering was stable across repeated subsample replicates. RCS showed a significant linear association ( p overall = 0.008), with an exploratory inflection near WWI ≈12.4. Higher WWI was associated with lower estradiol (E2) and sex hormone‐binding globulin (SHBG) and a higher total testosterone (TT)‐to‐SHBG ratio. Conclusions: WWI was cross‐sectionally associated with breast cancer prevalence after adjustment for age, race, PIR, hypertension, diabetes, and CHD, supporting its potential role as a simple marker of central adiposity in descriptive epidemiology.

  • Open Access

    MND1 reduces breast cancer chemosensitivity by promoting RAD51-mediated homologous recombination repair

    by Hao-Ran Yue, Zhi-Hao Yu, Hong-Meng Zhao, Lin-Yue Hai, Wen-Bo Liu, Xiao-Feng Liu, Zhao-Hui Chen, Yue Yu, Jie Ge, Xin Wang

    Breast cancer remains a major global health challenge for women. Chemotherapy resistance is a key driver of breast cancer recurrence and metastasis. Although meiotic nuclear division 1 (MND1) has been characterized as an oncogenic factor involved in mitotic progression and homologous recombination (HR), the precise molecular mechanisms underlying these MND1-mediated processes remain unclear. The expression of MND1 in breast cancer cell lines was evaluated by RT-qPCR and western blot. The functional effects of MND1 were assessed through a series of in vitro and in vivo assays, including cell proliferation assays, determination of resistance curves, DNA damage detection and flow cytometry. Protein interactions among MND1, RAD51, and USP5 were determined by co-immunoprecipitation assays. Transcriptional regulation of MND1 by E2F1 and promoter methylation status were analyzed using luciferase reporter assays and bisulfite sequencing PCR, respectively. We demonstrated that MND1 is upregulated in breast cancer and associated with cancer progression and cisplatin resistance. Mechanistically, MND1 promotes HR repair by recruiting USP5 to deubiquitinate and stabilize RAD51. Furthermore, E2F1 induces promoter hypomethylation and transcriptionally activates MND1 by binding to its promoter. Our findings establish a role for MND1 in regulating chemosensitivity and provide new insights into relevant gene interaction networks. The identified E2F1/MND1/USP5/RAD51 feedback loop underscores the potential of MND1 as a therapeutic target for breast cancer.


  • Open Access

    IRX1 suppresses breast cancer progression by inhibiting fatty acid de novo synthesis through downregulating ACACA expression

    by Wen-Bo Liu, Lin-Yue Hai, Yuan-Yuan Zhang, Hao-Ran Yue, Xiao-Feng Liu, Bo-Wen Liu, Xin Wang, Xu-Chen Cao, Yue Yu

    Breast cancer remains a major threat to women’s health and survival worldwide. Iroquois homeobox 1 ( IRX1 ), a developmentally regulated transcription factor, acts as a tumor suppressor in several cancers. However, its mechanistic role in breast cancer remains elusive. In this study, we demonstrate that IRX1 is downregulated in breast cancer tissues and cell lines due to promoter hypermethylation. IRX1 functioned as a tumor suppressor both in vitro and in vivo. Mechanistically, IRX1 interacts with NME1 and promotes its nuclear localization. Subsequently, NME1 facilitates the transcriptional regulation of ACACA by IRX1 . The IRX1 - NME1 axis modulates de novo fatty acid synthesis and breast cancer progression by targeting ACACA . In conclusion, our findings reveal that the IRX1- NME1 / ACACA axis plays a critical role in de novo fatty acid synthesis and breast cancer progression, providing new insights into gene regulatory interactions and highlighting its potential as a novel therapeutic target for breast cancer.


  • Open Access

    Multi-omics Data Reveal SLC9A3R2 Promotes Breast Cancer Progression and an Immunosuppressive Microenvironment

    by Zujin Chen, Yao Wang, Guixin Wang, Yue Yu, Xin Wang, Xuchen Cao

    The molecular mechanisms driving the occurrence and progression of breast cancer remain unclear, necessitating the identification of novel molecular biomarkers and therapeutic targets. This study aims to investigate the role of SLC9A3R2 (NHERF2) in breast cancer progression via an integrated multi-scale approach. Analysis of The Cancer Genome Atlas (TCGA) data revealed that SLC9A3R2 is upregulated at both protein and mRNA level in breast cancer tissues, related to advanced tumor stage and poor prognosis, especially in luminal subtypes. Functional enrichment analyses linked high SLC9A3R2 expression to epithelial-mesenchymal transition (EMT), estrogen response, and PI3K-AKT/MAPK signaling pathways. Additionally, SLC9A3R2 expression was negatively correlated with the infiltration level of CD8+ T cell as well as the expression of four main immune checkpoint molecules. Single-cell RNA sequencing analysis of patient samples revealed that SLC9A3R2-positive tumor epithelial cells mediate aberrant cellular communication with endothelial cells, fibroblasts, and macrophages via specific ligand-receptor pairs involving FN1, COL1A1, and COL1A2. Cell functional assays showed that knockdown of SLC9A3R2 significantly impaired the proliferation, migration, and invasion capacities of breast cancer cells. Our findings establish SLC9A3R2 as a key promoter of breast cancer progression, influencing both intrinsic oncogenic pathways and the extrinsic tumor microenvironment (TME), which provides a novel insight for breast cancer treatment.

  • Open Access

    Integrative multi-omics and radiomics reveal a TMSB10-driven cell state for non-invasive assessment and precision stratification in breast cancer

    by Gui-Xin Wang, Jun-Ming Cao, Cheng-Lu Lu, Yun-Lin Wang, Zi-Yi Chen, Chang-Qing Yang, Shuo Wang, Zhang-Yin Guo, Yue Yu, Shan Cheng, et al.

    Background: Tumor cell heterogeneity is a fundamental driver of breast cancer aggressiveness, underlying recurrence, metastasis, and therapy resistance. Understanding the biological characteristics and functions of specific tumor cell clusters in the tumor microenvironment is crucial for advancing precision oncology. Methods: We delineated breast cancer tumor cell heterogeneity by integrating single-cell transcriptomics, spatial transcriptomics, bulk transcriptomics, genomic and radiomic data. The oncogenic functions of the candidate gene TMSB10 were rigorously validated in vitro. To advance individualized patient management, we employed machine learning to develop a non-invasive MRI radiomic model for estimating tumor cluster abundance and a robust prognostic signature for risk stratification. Results: We discovered a poor-prognosis tumor cell cluster (C1 cluster). C1 cluster exhibited a late evolutionary state, metabolic reprogramming (OXPHOS/glycolysis), and active crosstalk with cancer-associated fibroblasts and endothelial cells. High abundance of C1 cluster was associated with poor survival, specific somatic mutations, and predicted superior response to immune checkpoint blockade, but not to chemo/radiotherapy. The radiomic model based on MRI images was exploratively established for estimating the abundance of C1, and the prognostic model based on C1-derived genetic features significantly stratified the survival risk of breast cancer in multiple cohorts. In vitro experiments confirmed that TMSB10 , a C1 core gene, promotes proliferation, migration, invasion. Conclusions: This study revealed C1 cluster as a key driver of breast cancer progression and its application for predicting immunotherapy response. Additionally, TMSB10 was identified as a functional effector of C1 cluster, providing a new and applicable clinical tool for non-invasive detection and prognostic stratification for breast cancer.


  • Open Access

    RAN-S100A10-EGFR axis facilitates papillary thyroid cancer metastasis by PI3K/AKT signaling

    by Wenbin Song, Zhaoyi Liu, Cangchang Shi, Guixin Wang, Long He, Zhaohui Chen, Yingxi Li, Yue Yu, Ruoyu Jiang, Xiaoning Wang, et al.

    Background: The incidence of thyroid cancer has been increasing in recent years, with papillary thyroid carcinoma (PTC) accounting for the majority of cases. Accumulating studies have demonstrated that S100A10 acts as an oncogene in the progression of various malignancies. However, the function and specific mechanisms of S100A10 in thyroid cancer remain poorly defined. Methods: Single-cell RNA sequencing data of PTC from public databases were analyzed to screen differentially expressed genes (DEGs), among which S100A10 emerged as a potential biomarker associated with PTC metastasis and prognosis. The expression of S100A10 in tissues and cell lines were validated by RT-qPCR and western blot. Protein-protein interactions were confirmed using mass spectrometry analysis and co-immunoprecipitation. The subcellular localization of the protein was determined by immunofluorescence. Stable PTC cell lines overexpressing S100A10 were constructed and followed by transwell assays, wound-healing assays, and western blot for EMT capability detection. Results: S100A10 was found to play essential roles in tumor metastasis and was associated with unfavorable prognosis in patients with PTC. S100A10 was expressed higher in both PTC tissues and cells. Furthermore, both in vitro and in vivo experiments confirmed that S100A10 activates the PI3K/AKT signaling and promotes EMT in PTC cells, enhancing the invasive capabilities of tumors. S100A10 could interact with both RAN and EGFR intracellularly, forming a RAN-S100A10-EGFR regulatory axis. Finally, several potential drugs targeting S100A10 were identified for further in-depth research. Conclusion: These findings clarify the role of S100A10 and RAN in PTC progression and highlight their potential as therapeutic targets, linking EMT with PI3K/AKT signaling.


  • Open Access

    HSPA6 Promotes Ferroptosis in Triple-Negative Breast Cancer by Rewiring Lipid Metabolism to Potentiate Membrane Lipid Peroxidation

    by Lin-Yue Hai, Zhi-Hao Yu, Wen-Bo Liu, Yuan-Yuan Zhang, Yue Xu, Shan Cheng, Hao-Ran Yue, Zhang-Yin Guo, Shi-Jie Yan, Rui Sun, et al.

    Given the lack of effective targeted therapeutic options for triple-negative breast cancer (TNBC), there is an imperative demand for innovative treatment approaches, with ferroptosis standing out as a promising direction. This study identifies HSPA6 as a key ferroptosis sensitizer in TNBC. Mechanistically, HSPA6 binds to NF-κB p65, inhibits its nuclear translocation and Ser468 phosphorylation, thereby suppressing transcription of the lipogenic enzyme FASN and downregulating phospholipid-remodeling enzymes LPCAT1/cPLA2. This dual inhibition enriches membrane phospholipids with polyunsaturated fatty acids, heightening peroxidation susceptibility and triggering ferroptosis. Concurrently, HSPA6-mediated suppression of lipogenesis depletes palmitate, thereby attenuating ANKIB1 palmitoylation and inhibiting its E3 ligase activity. This impairs K48-linked ubiquitination and degradation of HSPA6, forming a stabilizing positive feedback loop. Our study uncovers a HSPA6-p65-FASN-ANKIB1 axis linking lipid metabolism to ferroptosis, offering a novel TNBC therapeutic target.


  • Subtype-specific APOBEC enrichment links genomic instability to predict immunotherapy response in breast cancer subtypes

    by ZeWei Zhao, JiaQi Zhou, WenBin Jia, Yongjie Xie, Yaoyao Zhou, ChunLan Ning, XuChen Cao, Yue Yu, Xin Wang


  • Targeting the SIN1 mediated TTK/LDHA-H3K18la-GLUT3 axis disrupts metabolic-epigenetic crosstalk and suppresses progression in hyperglycolytic breast cancer

    by Zewei Zhao, Wenbin Jia, Zekun Li, Shangheng Shi, Jiaqi Zhou, Chunlan Ning, Zhihao Yu, Xiaofeng Liu, Xuchen Cao, Hong Zheng, et al.


  • Open Access

    Changes in HER2, ER, PR, and Ki-67 in HER2-Negative Breast Cancer After Neoadjuvant Chemotherapy: A Case–Control Study

    by Youzhao Ma, Yan Yang, Mingda Zhu, Yue Yu, Xin Wang

    Purpose: This study investigates receptor status changes following neoadjuvant chemotherapy (NAC) in breast cancer, aiming to identify new therapeutic opportunities and improve human epidermal growth factor receptor 2 (HER2) detection and categorization methods. Methods: This retrospective analysis was conducted on patients with breast cancer who underwent NAC and surgery between July 2022 and June 2024. Chi-square tests and logistic regression models were applied to assess the associations between HER2 status changes and clinicopathological features. Results: Among 508 patients, the receptor discordance rates after NAC were 5.3% for estrogen receptor (ER), 21.3% for progesterone receptor (PR), and 43.7% for HER2. Ki-67 expression decreased in 64.6% of cases and increased in 6.8%. Of the 103 patients with HER2-0, 47 (45.6%) transitioned to IHC 1+, 9 (8.7%) to IHC 2+/ISH−, and 1 (1.0%) to IHC 2+/ISH+. Among 256 patients with HER2 IHC 1+, 58 (22.7%) transitioned to IHC 2+/ISH−, 36 (14.1%) to IHC 0, and 9 (3.5%) to IHC 2+/ISH+. For 149 patients with HER2 IHC 2+/ISH−, 50 (33.6%) transitioned to IHC 1+, 6 (4.0%) to IHC 2+/ISH+, 5 (3.4%) to IHC 0, and 1 (0.7%) to IHC 3+. Univariate analysis revealed that, when compared to grade III tumors, grade I–II tumors exhibited a higher rate of HER2-0 to HER2-low conversion (66.7% vs. 36.8%, p = 0.027). HER2-low to HER2-0 conversion was associated with ER negativity (p = 0.028), PR negativity (p = 0.021), HER2 IHC 1+ (vs. IHC 2+, p = 0.001), and TIL >10% (p = 0.049). Multivariate analysis revealed that tumors with HER2 IHC 1+ were more likely to convert to HER2-0 after NAC than those with HER2 IHC 2+ (p = 0.020). Conclusions: Following NAC, ER gain, PR loss, and Ki-67 reduction were common. HER2 and ER status changes predominantly occurred within adjacent expression intensity levels.